Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

To Identify if a COPD Self-management App Can Safety and Appropriately Identify When Patients Are Not on the Best Medication Plan for Their COPD Symptoms and Support Their COPD Management. (mySmartCOPD)

28 de agosto de 2026 atualizado por: University of Southampton

To Explore the Safety and Clinical Efficacy of a Treatment Realignment Algorithm Using Data From a Digital Self-management Application for Patients With COPD

Although COPD cannot be cured, managing COPD can help reduce symptoms control, slows progression of the disease, and may improve the quality of life. Management of COPD becomes less effective when healthcare professionals fail to prescribe appropriate inhaled therapies, due to poor adherence to evidence-based guidelines and underdiagnosis, or when patients fail to adhere to prescribed treatment regimens.

my mhealth has developed an app called myCOPD to allow patients to record their COPD symptoms and medications, which in term supports them with their COPD. This app is now used by COPD patients across the UK, via a prescription from their healthcare professionals. my mHealth has now developed a research app MMH-LAB1 which, in the intervention arm, includes an algorithm to assist patients with understanding their level of symptom burden according to the severity of their daily symptoms and exacerbation risk. The algorithm then analyses current patient prescribed inhaled medication against those recommended by the GOLD 2023 report and informs the patient via the MMH-LAB1 app as to whether their medication needs to be changed by their healthcare provider. This trial will explore whether the introduction of the algorithm within the MMH-LAB1 app can be used as a safe, effective and acceptable tool to assist patients to achieve optimal guideline based inhaled therapy and therefore provide greater symptom control and lowered exacerbation risk for COPD patients.

Participants will be randomised to the MMH-LAB1 app - control arm (MMH-LAB_Control_1 where participants just record COPD symptoms and medications), or to the MMH_LAB1 app - intervention arm (MMH-LAB1_Test_1 where participants record their COPD symptoms and medication plus receiving information from the algorithm, as to whether their medications are in guidance or not, and if not, be notified to visit their healthcare professional.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

This study is an open-label randomised control trial with inbuilt pilot phase and qualitative sub-study:

Phase 1 (pilot - 50 participants): Interim futility analysis on adherence to intervention advice Phase 2 (efficacy - 746 participants (including pilot phase participants): Safety acceptability and efficacy of intervention. This includes the qualitative sub study 15-20 participants (from the 746 Phase 2 participants).

Qualitative Sub-study: Acceptability of the intervention (15-20 intervention participants)

This trial will explore whether the introduction of the treatment realignment algorithm can be used as a safe, effective and acceptable tool to assist patients to achieve optimal, guideline based inhaled therapy and therefore provide greater symptom control and lowered exacerbation risk for COPD patients. To assess effect of the intervention on patients' symptom control, including exacerbation frequency and patient wellness scores.

Main objectives

  • To understand the intervention pathway in the pilot phase and to identify additional patient support mechanisms for the efficacy phase in order to maximise healthcare equality
  • To assess the levels of app usage and engagement
  • To assess patients' experience of using the intervention

Study Design:

Open-Label Randomised Control Trial with inbuilt pilot phase Qualitative Sub study:

Phase 1 (Pilot): Interim futility analysis on adherence to intervention advice Phase 2 (Efficacy): Safety, acceptability and efficacy of intervention Qualitative Sub-study: Acceptability of the intervention.

The research question is to explore the safety and efficacy of the treatment re-alignment algorithm as part of a digital self-management application (app) in patients with COPD.

Tipo de estudo

Intervencional

Inscrição (Estimado)

746

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • England
      • Southampton, England, Reino Unido, SO16 6YD
        • Recrutamento
        • University Hospital Southampton
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Sim

Descrição

Inclusion Criteria:

  1. Adult patients over 18 years of age and able to give informed consent
  2. A clinical diagnosis of COPD (all patients registered on the app have a confirmed diagnosis of COPD confirmed by their clinician before being prescribed the app).
  3. A registered and activated user of the myCOPD app
  4. One or more CAT questionnaire completed on the myCOPD app in the last 12 months
  5. One or more exacerbation form completed on the myCOPD app in the last 12 months CTU/FORM/5321 - CIP template for Clinical Investigations of Medical Devices, Version 1 14-DEC-2023 mySmartCOPD Clinical Investigation Plan v1 25-FEB-2025 Page 25 of 53
  6. One or more COPD medication diary completed on the myCOPD app in the last 12 months
  7. Classified appropriately into 3 groups:

    (A) Few symptoms (CAT <10, 0 or 1 moderate exacerbations) (B) Many symptoms (CAT ≥10, ≥0 or 1 moderate exacerbations) (C)Exacerbators (≥2 moderate or ≥1 severe exacerbation independent of CAT)

    Exclusion Criteria:

  8. Cannot read or write in English as required to understand the trial materials and provide the trial data.
  9. Has not opted in to the research agreement via MyCOPD

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Cuidados de suporte
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador de Placebo: MMH-LAB1 Control This arm is based on the original COPD app the participants already use
Participants for this study are already users of a COPD self management app. This arm is a replica of this app, with additional questionnaires built in
This app is based on a COPD self management app, which they are already using and includes an algorithm which will notify participants if there is a discrepancy between the symptoms they report onto the app and their medication regime, and informs them to approach their healthcare provider for a medication review
Experimental: MMH-LAB1 Test This arm is based on the original COPD app the participants use plus an algorithm
Participants for this study are already users of a COPD self management app. This arm is a replica of this app, with additional questionnaires built in plus an algorithm which identifies, based on the symptoms and medication reported onto the app by the participant, whether they are on the correct medication or not. If not, the app will generate a notification and inform the participant that they need to approach their healthcare provider and inform them of this and that they need a medication review.
This app is based on a COPD self management app, which they are already using and includes an algorithm which will notify participants if there is a discrepancy between the symptoms they report onto the app and their medication regime, and informs them to approach their healthcare provider for a medication review

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
To determine the safety, acceptability and efficacy of a digital treatment guidance algorithm for inhaled treatment in patients with COPD. The intention is to measure the impact of the algorithm in prompting patients to achieve optimal management, and t
Prazo: 6 months
Proportion (measured in %) of participants receiving guideline adherent treatment at Baseline and trial completion (Month 6). Range 0%-100%.
6 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
To assess effect of intervention on exacerbation frequency and patient wellness scores
Prazo: 6 months

• Change in COPD Assessment Test (CAT) score between Baseline and trial completion (Month 6)

CAT test results 0 minimal symptom impact - Best and 40 maximum symptom impact

All will be described in terms of:

  • Mean and SD
  • Median and range and will be reported as descriptive stats
6 months
To assess effect of the intervention on patients' adherence to guideline mandated treatment
Prazo: 6 months

- Rate of indication of algorithm to change treatment (0 times to 150 times)

• Rate if change in response to treatment change indication (0 times to 150 times)

All measured via frequency and percentage and description of change.

The combination of measurements will be reported as descriptive stats

6 months
To understand the utility of the intervention pathway in the pilot phase and to identify additional patient support mechanisms for the efficacy phase in order to maximise healthcare equality
Prazo: 6 months

- % Patients receiving guideline adherent treatment at Baseline and trial completion (Month 6). 100% good. 0 % bad.

Above described qualitatively and in terms of % and frequency

6 months
To assess the levels of app algorithm usage and engagement
Prazo: 6 months

-Frequency of app engagement

  • Rate of completion of endpoint data
  • Resource requirement to allow patients to act on intervention information

Measured by frequency (numbers of participant who completed everything) % (0% of expected use bad and 100% of expected use good). This will be reported as descriptive stats.

6 months
To understand patients' experience of using the intervention
Prazo: 3-6 months - interviews. 6 months - feedback questionnaire

This section relates to the qualitative sub-study and will look at the following:

- Patient experience and patient and patient advocate feedback on experience of using app

• Patient satisfaction Rating using the Patient

Using feedback questionnaire at month 6 and qualitative interviews as part of the sub -study

  • Qualitative data will be thematically analysed and written up in a report. Tables will be produced outlining key themes and illustrative quotes
  • Frequency and percentage.
  • Means and standard deviations.
  • Statistical tests may be performed to explore any difference in experience of using the intervention relative to cohort groupings

This will be reported in a separate analysis document using qualitative research analysis and reporting techniques and norms

3-6 months - interviews. 6 months - feedback questionnaire
To assess the safety of the algorithm
Prazo: 6 months

• Rate of algorithm inappropriately firing notifications

This is data collected via MMHLAB apps and qualitatively via patient advocate.

  • Frequency and percentage. (0 times good, not maximum time - But anything over 0 is bad)
  • Means and standard deviations.
6 months
To assess the change in frequency of exacerbations
Prazo: 6 months
Frequency of exacerbation between Baseline and trial completion (Month 6) • Frequency and percentages (for number of exacerbations) Frequency will be measured from 0-150 with 0 being optimal. This will be reported as descriptive stats.
6 months
To assess the change in Quality of Life between baseline and 6 months
Prazo: 6 months
Change in Quality of Life. Ratings measured using EQ-5D questionnaire between Baseline and trial completion (Month 6). All will be described in terms of: • Mean and SD • Median and range. Score 11111 will be classed as full health and 55555 will be classed worst health. This will be reported as descriptive stats
6 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

8 de outubro de 2025

Conclusão Primária (Estimado)

1 de setembro de 2026

Conclusão do estudo (Estimado)

1 de setembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

7 de maio de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

28 de agosto de 2026

Primeira postagem (Real)

1 de setembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

1 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

28 de agosto de 2026

Última verificação

1 de maio de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • 355764
  • AI_Award02200 (Número de outro subsídio/financiamento: UK - National Institute for Health and Care Research)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .